Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | ACP3 | P15309 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6865830 | 0.91 | CES1 (0.41) | CES1ALDH1A1CHRM2OPRM1DDB1 | |
| SCHEMBL30703123 | 0.79 | CRBN (0.57) | ALDH1A1CHRM2OPRM1DDB1CRBN | |
| SCHEMBL15028540 | 0.79 | CRBN (0.57) | ALDH1A1CHRM2OPRM1DDB1CRBN | |
| SCHEMBL2557698 | 0.79 | CRBN (0.57) | ALDH1A1CHRM2OPRM1DDB1CRBN | |
| SCHEMBL30998388 | 0.76 | OPRM1 (0.50) | ALDH1A1CHRM2OPRM1DDB1CRBN | |
| SCHEMBL1265932 | 0.76 | OPRM1 (0.50) | ALDH1A1CHRM2OPRM1DDB1CRBN | |
| SCHEMBL1264462 | 0.76 | OPRM1 (0.50) | ALDH1A1CHRM2OPRM1DDB1CRBN | |
| SCHEMBL252576 | 0.75 | KDM1A (0.55) | ALDH1A1TSHRKDM1AKMT2ANPSR1 | |
| SCHEMBL12288907 | 0.74 | KDM1A (0.69) | ALDH1A1TSHRKDM1AKMT2ANPSR1 | |
| SCHEMBL31675930 | 0.72 | SPPL2A (0.42) | KDM1AKMT2AKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893071-B2 | Substituted phthalimide and isoquinoline derivatives; thalidomide analogs that lack the piperidine-2,6-dione moiety of thalidomide | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893071-B2 | Substituted phthalimide and isoquinoline derivatives; thalidomide analogs that lack the piperidine-2,6-dione moiety of thalidomide | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893071-B2 | Substituted phthalimide and isoquinoline derivatives; thalidomide analogs that lack the piperidine-2,6-dione moiety of thalidomide | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-02-22 | — | — | US | disclosed |
| US-20040122030-A1 | Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122030-A1 | Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic | KDR, FLT4, FLT1 | CES1 2251/4885ALDH1A1 1161/4885CHRM2 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.